NEW YORK CITY, NY / ACCESS Newswire / March 14, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

TD Cowen analyst Charles Rhyee lowered the firm’s price target on Fortrea (FTRE) to $11 from $20 and keeps a Hold rating on the shares. The ...

Fortrea Holdings Inc. (NASDAQ:FTRE – Get Free Report) has received a consensus rating of “Reduce” from the twelve analysts that are currently covering the stock, MarketBeat Ratings reports.

DURHAM, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that it will appoint Erin L. Russell, a financial and ...

Fortrea Holdings Inc., a prominent player in the U.S. Life Science Tools & Diagnostics sector, has been navigating a complex market landscape characterized by divergent trends across its key ...

Clinical research company Fortrea Holdings (NASDAQ:FTRE) will be reporting earnings tomorrow before market hours. Here’s what investors should know. Fortrea met analysts’ revenue expectations ...

Fortrea (NASDAQ:FTRE – Get Free Report)‘s stock had its “market perform” rating reissued by equities researchers at William Blair in a research note issued on Tuesday,Benzinga reports.

On Monday, TD Cowen's analysts revised their outlook for Fortrea (NASDAQ: FTRE), a company operating in the contract research organization (CRO) industry. The firm's price target for Fortrea ...

Fortrea Holdings Inc., a prominent player in the U.S. Life Science Tools & Diagnostics sector, has been navigating a complex market landscape characterized by divergent trends across its key business ...

In a recent interview with Fierce Biotech's Chris Hayden, Fortrea's Chief Technology and Data Officer Alaric Jackson discussed the growing role of AI in clinical trials. Jackson described how AI ...